Russell Investments Group
ERNA icon

Russell Investments Group’s Eterna Therapeutics ERNA Stock Holding History

Russell Investments Group’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2
Closed -$25K – 2907
2022
Q1 		$25K Buy
+2
New +$37.9K ﹤0.01% 2670

Other funds holding ERNA

CPWM
Cypress Point Wealth Management Dallas, Texas $492M AUM 22.57% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $801M AUM 22.2% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IC
Inverness Counsel New York $1.8B AUM 9.9% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Russell Investments Group's ERNA Position: Q2 2022 in Review

Russell Investments Group sold out of Eterna Therapeutics (ERNA) in Q2 2022, closing a stake of 2 shares — an estimated $25K sold.

Russell Investments Group first reported a position in ERNA in Q1 2022 and held it in 1 quarter. The position peaked at $25K in Q1 2022. 34 funds tracked by Wall St. Rank hold ERNA as of Q2 2022.

  • Russell Investments Group reported no remaining Eterna Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Russell Investments Group sold 2 Eterna Therapeutics shares in Q2 2022, an estimated $25K.
  • Russell Investments Group first reported a position in Eterna Therapeutics in Q1 2022 and held it in 1 quarter.
  • Russell Investments Group's Eterna Therapeutics position peaked at $25K in Q1 2022.
  • 34 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2022.

Based on Russell Investments Group's 13F filing for Q2 2022, filed 29 Jul 2022.